The Lancet: New Treatment Programme to Eliminate Mother-to-Child Transmission of AIDS

AIDS remains an important infectious disease affecting global health, and mother-to-child transmission is one of its three main routes of transmissionAbout 1.6 million people living with HIV become pregnant each yearIn many HIV-endemic areas, the inability to suppress HIV hiv load to a low enough level before the birth is a major challenge in blocking mother-to-child transmission and reducing infant mortalityThe Lancet-AIDS recently published a major trial led by a team at the University of Liverpool in the UK, bringing the solution to this problemTreatment sprees based on the new anti-HIV drug dolutegravir can also safely and rapidly suppress HIV in pregnant women, reducing the risk of mother-to-child transmission in women at high risk of HIV during pregnancy and breastfeedingin a commentary published in the same issue,, DrDrDnirvi," said DrDorutwe's program provides a huge opportunity to improve HIV suppression in pregnant women and address key gaps in eliminating mother-to-child transmission of HIVScreenshot Source: The Lancet HIVthe biggest risk period of mother-to-child transmission is during childbirthFor PEOPLE LIVING WITH HIV, THE INCIDENCE OF MOTHER-TO-CHILD TRANSMISSION IS ABOUT 15 TO 45 PER CENT WITHOUT THE ACCEPTANCE OF ANTIRETROVIRAL THERAPY (ART), A RISK THAT CAN BE REDUCED TO 5 PER CENT IN THE EARLY STAGES OF PREGNANCYHowever, in Africa, where more than two-thirds of the world's living people live with HIV, there are a large number of pregnant women who usually receive obstetric care in the last trimester of pregnancy, at a time when existing first-line treatments based on legal virenz do not have enough treatment time to prevent mother-to-child transmissionThe initiation of ART treatment in late pregnancy is associated with a seven-fold increase in the risk of mother-to-child transmission of AIDS and a doubling of the risk of death in infants within a year, on the other hand, a World Health Organization survey also shows that in the past few years, 12 countries in Africa, Asia and the Americas have been more resistant to the core drugs ethanvrem and nevirapine than they are acceptablePhoto Credit: C GoldsmithContent Providers: CDC/C Goldsmith, P Feorino, E L Palmer, W R McManus (Public domain), via Wikimedia Commons in non-pregnant adult patients, the new anti-HIV drug doutwevir suppressoid virus is much faster than the current recommended therapy, and the viral load drops to an undetectable level (50 copies/mL) for a median treatment time of 28 days This feature is a potential advantage for late-pregnancy initiation therapy, but the lack of randomized trial data makes it unclear whether Dorutwe is safe and effective in pregnant women to fill this gap, the large-scale clinical trial, called DolPHIN-2, was conducted in Uganda and South Africa, including 268 pregnant women over the age of 18 who were diagnosed with HIV but were at least 28 weeks pregnant between January 23 and August 15, 2018, who were randomly treated with ART treatment containing Drutwe (135) or based on the standard art treatment of Verviron (133) results showed that 74 percent of women who received the Doutwe programme in late pregnancy had reduced their viral load at the time of delivery to undetectable levels - a virus that could not be transmitted if the level of the virus could not be detected, according to the concept of "undetectable equals" untransmittable Of the women who received the legal Wellen programme, only 43 per cent met that standard after treatment, the hiv carrier dropped to undetectable levels in both groups of women (Photo: Source: Supplied) And 11% of the legal Veren group reported severe adverse events, respectively, mainly due to longer pregnancy weeks for more people in the former There was no significant difference in production between the two groups at 37 or 34 weeks The team found that both programs were generally well tolerated in both cases, with adverse events similar to those found in large-scale trials of previously unpregnant adults, but the impact on maternal and infant safety needed to be continued in more studies Professor Saye Khoo, of the University of Liverpool, author of the study, said the results "highlight a significant difference in the speed of the two drug-suppressing viruses." This is important because many African women only find out they are infected with HIV in the late stages of pregnancy, making it difficult to prevent mother-to-child transmission in addition, three babies in the Dorutwe programme group tested positive for HIV infection shortly after birth, two of them had their postpartum viral load dropped to undetectable levels and one mother's viral load was at very low levels, so the team believed it could be intrauterine transmission It is also a reminder that, despite the significant improvements that Dorutwe has brought, it is not foolproof that pre-pregnancy and treatment throughout pregnancy and throughout pregnancy and lactation can further eliminate mother-to-child transmission currently, WHO guidelines recommend a gradual transition to the use of doutwevir-based drugs in first-line antiretroviral therapy The team stressed that the study's data supported whose guidelines were revised to give women in advanced pregnancy the confidence to receive drugs that rapidly inhibit viral load Professor Saye Khoo, , said: "Last year, more than 100,000 babies worldwide were infected with HIV Mother-to-child transmission of HIV is preventable, and we have a responsibility to ensure that the burden of AIDS is not passed down from generation to generation "
expect better treatment options and the widespread implementation of other interventions to prevent mother-to-child transmission, which can take us one step closer to the goal of eliminating global mother-to-child transmission of HIV Reference s Kenneth Kintu, et al., (2020) Dolutegravir versus efavirenz in women starting HIV therapy in late gey (DolPHIN-2): an open-label, randomised controlled trial The Lancet HIV, DOI: 10.1016/S2352-3018 (20) 30050-3 (2020) Opportunities and limits for dolutegravir in late gey The Lancet HIV, DOI: 10.1016/S2352-3018 (20) 30071-0 3 Results of 'highly of the name' HIV transmission Retrieved May 19, 2020, from https://medicalxpress.com/news/2020-05-results-highly-significant-hiv-transmission.html 4' Alarming sanath in drug-resistant HIV ed Retrieved May 19, 2020, from https:// Hoyd May 19, 2020, from https:// original title: The Lancet sub-issue: Eliminating mother-to-child transmission of AIDS, the new treatment solution solves this critical problem!